Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11590354 | 0.79 | — | — | |
| SCHEMBL28335464 | 0.74 | F2 (0.59) | F2 | |
| SCHEMBL11431837 | 0.73 | — | — | |
| SCHEMBL8770491 | 0.72 | — | — | |
| SCHEMBL737372 | 0.71 | ALDH1A1 (0.31) | — | |
| SCHEMBL11591942 | 0.65 | — | — | |
| SCHEMBL18053059 | 0.61 | NPC1 (0.36) | — | |
| SCHEMBL11143880 | 0.61 | — | — | |
| SCHEMBL11211913 | 0.60 | — | — | |
| SCHEMBL594489 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118496175-A | TRADD inhibitor derivative and preparation method and application thereof | 安徽医科大学 | 2024-08-16 | — | — | CN | claimed |
| CN-117399635-B | Gold nanoparticle and preparation method and application thereof | 中国科学院遗传与发育生物学研究所 | 2024-03-29 | — | — | CN | claimed |
| CN-117399635-A | Gold nanoparticle and preparation method and application thereof | 中国科学院遗传与发育生物学研究所 | 2024-01-16 | — | — | CN | claimed |
| JP-52079081-A | — | — | None | — | — | JP | disclosed |
| CN-118496175-A | TRADD inhibitor derivative and preparation method and application thereof | 安徽医科大学 | 2024-08-16 | — | — | CN | disclosed |
| CN-117399635-B | Gold nanoparticle and preparation method and application thereof | 中国科学院遗传与发育生物学研究所 | 2024-03-29 | — | — | CN | disclosed |
| CN-117399635-B | Gold nanoparticle and preparation method and application thereof | 中国科学院遗传与发育生物学研究所 | 2024-03-29 | — | — | CN | disclosed |
| CN-117399635-A | Gold nanoparticle and preparation method and application thereof | 中国科学院遗传与发育生物学研究所 | 2024-01-16 | — | — | CN | disclosed |
| CN-117399635-A | Gold nanoparticle and preparation method and application thereof | 中国科学院遗传与发育生物学研究所 | 2024-01-16 | — | — | CN | disclosed |
| EP-1801108-B9 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-11-20 | — | — | EP | disclosed |
| EP-1801108-B1 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7935700-B2 | Morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20070265257-A1 | Morpholine Compound | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1801108-A1 | MORPHOLINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-06-27 | — | — | EP | disclosed |
| US-4656262-A | 7-methoxy cephalosporin derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1987-04-07 | — | — | US | disclosed |
| US-4242449-A | 7-Methoxy cephalosporins and process of producing them | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1980-12-30 | — | — | US | disclosed |
| US-4165429-A | 7α-METHOXY-CEPHALOSPORANIC ACID DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1979-08-21 | — | — | US | disclosed |
| US-4068074-A | BACTERICIDES | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1978-01-10 | — | — | US | disclosed |
| JP-S5279081-A | PREPARATION OF NOVEL 7-METHOXYCEPHALOSPORINS | YAMANOUCHI PHARMACEUT CO LTD | 1977-07-02 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265257-A1 | Morpholine Compound | CCR3, CCR1, CCR4 | F2 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.